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Abstract
Background:  New artemisinin combination therapies pose difficulties of implementation in
developing and tropical settings because they have a short shelf-life (two years) relative to the
medicines they replace. This limits the reliability and cost of treatment, and the acceptability of this
treatment to health care workers. A multi-pronged investigation was made into the chemical and
physical stability of fixed dose combination artemether-lumefantrine (FDC-ALU) stored under
heterogeneous, uncontrolled African conditions, to probe if a shelf-life extension might be possible.
Methods: Seventy samples of expired FDC-ALU were collected from private pharmacies and
malaria researchers in seven African countries. The samples were subjected to thin-layer
chromatography (TLC), disintegration testing, and near infrared Raman spectrometry for
ascertainment of active ingredients, tablet integrity, and chemical degradation of the tablet
formulation including both active ingredients and excipients.
Results: Seventy samples of FDC-ALU were tested in July 2008, between one and 58 months post-
expiry. 68 of 70 (97%) samples passed TLC, disintegration and Raman spectrometry testing,
including eight samples that were post-expiry by 20 months or longer. A weak linear association
(R2 = 0.33) was observed between the age of samples and their state of degradation relative to
brand-identical samples on Raman spectrometry. Sixty-eight samples were retested in February
2009 using Raman spectrometry, between eight and 65 months post-expiry. 66 of 68 (97%) samples
passed Raman spectrometry retesting. An unexpected observation about African drug logistics was
made in three batches of FDC-ALU, which had been sold into the public sector at concessional
pricing in accordance with a World Health Organization (WHO) agreement, and which were
illegally diverted to the private sector where they were sold for profit.
Conclusion: The data indicate that FDC-ALU is chemically and physically stable well beyond its
stated shelf-life in uncontrolled, tropical conditions. While these data are not themselves sufficient,
it is strongly suggested that a re-evaluation of the two-year shelf-life by drug regulatory authorities
is warranted.
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Background
Improving access to effective anti-malarial treatment is a
priority of most donors, United Nations agencies and
national governments. In Africa and Asia, where the dis-
ease is most prevalent, limited health care infrastructure
complicates efforts to predict clinical demand, procure,
distribute, and administer medicines during their
approved shelf-life. This typically results in purchasers
procuring too little medicine, causing stock-outs and
excess mortality, or purchasing too much medicine, caus-
ing overstock and drugs expiring on the shelf [1].
This logistical tight-rope act is more complicated than ever
because chloroquine, with a shelf-life of up to five years,
has been superseded as the standard of care by artemisi-
nin-based combination therapy (ACT), such as a fixed
dose combination artemether-lumefantrine (FDC-ALU),
with a shelf-life of only two years. The reduction in shelf-
life has contributed to serious disruptions in treatment
availability in clinics; reluctance among health care work-
ers to adopt the higher standard of care; and practical
questions about whether large-scale home treatment
schemes for malaria are feasible [2-4]. Globally, the
shorter shelf-life also reduces the margin for error that
pharmaceutical manufacturers and large purchasers, like
health ministries, have to move in lockstep and balance
demand with supply – a balance that, when upset, has
caused global shortages and price spikes [5].
Currently, FDC-ALU is one of the dominant forms of ACT.
That it has a two-year shelf-life is a legacy of history. FDC-
ALU was first registered with the drug regulatory authori-
ties in Switzerland where, in accordance with Interna-
tional Conference on Harmonization guidelines, the
shelf-life of a medicine is extrapolated from accelerated
laboratory stability tests, usually by adding 12 months to
the duration of those tests (e.g. if the accelerated labora-
tory stability tests are good at 12 months, the regulator
can grant an approved shelf-life of 24 months) [6].
Approvals for over two years usually are not based solely
on accelerated stability testing, but also on long-term sta-
bility data collected in real time (e.g. approval for a five-
year shelf-life may require five years of tests). Other agen-
cies, including the WHO, ordinarily do not question the
two-year shelf-life that FDC-ALU has today.
The goal of this study was to assess the physical and chem-
ical stability of expired FDC-ALU under tropical field con-
ditions, as a preliminary step toward possibly
reexamining and extending the authorized shelf-life. If
future and more detailed studies indicate this step were
warranted, one could potentially simplify the logistics and
reduce the cost of ACT delivery, further displacing obso-
lete medicines, such as chloroquine, with implicit gains to
treatment effectiveness.
Methods
Seventy samples of expired FDC-ALU were collected at
random from private pharmacies and kiosks in major cit-
ies of Kenya, Mozambique, Nigeria, Rwanda, Tanzania,
Uganda and Zambia, as well as from malaria researchers'
personal supplies. These samples had not been stored
under ideal environmentally controlled conditions, but
rather under heterogeneous (and often suboptimal)
"field" conditions. To exclude flagrant counterfeits, pack-
aging was visually inspected for correctness and the batch
numbers were confirmed with the apparent manufacturer
(no such counterfeits were found).
Sixty-eight of the samples were confirmed to have been
manufactured by Novartis Pharmaceuticals AG (Coartem®
and Riamet®, which are identical products), and two sam-
ples were confirmed to have been manufactured by Cipla
Ltd (Lumartem®). Unexpired manufacturers' products for
use as analytical standards were procured either by pur-
chase and donation (in the case of Coartem/Riamet) or by
purchase alone (in the case of Lumartem). Further, to
independently corroborate the active ingredient in the
manufacturers' standards, a master FDC-ALU standard
was obtained from the Global Pharma Health Fund
(Frankfurt).
In July 2008, primary screening of samples was conducted
by the Global Pharma Health Fund e.V. Minilab® proto-
col, published elsewhere [7]. Semi-quantitative thin-layer
chromatography (TLC) and disintegration tests were per-
formed on each sample to determine tablet integrity and
the presence and amount of active ingredients, relative to
the master standard. Two tablets from each sample were
separately tested, and per the Minilab® protocol, a "pass"
was awarded if 80% or more of both labeled active ingre-
dients was present. (In the results no samples failed TLC,
so there was perfect agreement between the duplicates.)
Quality control of the Minilab was performed daily prior
to field drug testing and consisted of performing TLC on
Minilab-reference samples for the drugs being analyzed.
In addition, Minilab reagents were quality control tested
using reference samples when a new lot was introduced.
Secondary screening of samples was conducted using a
portable Raman spectrometer, operated per the manufac-
turer's protocol (TruScan; Ahura Scientific, Inc., Wilming-
ton, MA). This technique has been used in earlier studies
to discern counterfeit from legitimate anti-malarials in situ
[8,9]. Because Raman spectrometry is sensitive to the
excipients in the tablet and not solely the active ingredi-
ents, samples of Coartem/Riamet and Lumartem must be
tested with reference to the manufacturers' standards. The
TruScan device's laser is capable of reading through blister
packaging, but in these tests tablets were removed and
held in a constant distance and orientation during testing.Malaria Journal 2009, 8:33 http://www.malariajournal.com/content/8/1/33
Page 3 of 7
(page number not for citation purposes)
Samples were tested by Raman spectrometry on two occa-
sions: initial testing at the same time as TLC (in July
2008), and retesting seven months later after being stored
for that interval in a temperature-controlled office (in Feb-
ruary 2009). Two tablets from each sample had their spec-
tra measured using near infrared excitation (at 785 nm)
and continuous readout of Raman shift spectrum from
250 to 2875 cm-1. The discrepancy between the spectra of
the sample tablet and the standard is reflected in an over-
all figure of merit (p-value) generated by the TruScan
device. It is expected that newer samples will have smaller
discrepancies and higher p-values than older samples,
which experience cumulative chemical degradation over
time. A p-value below 0.05 corresponds to failure of the
test.
Results
The samples collected in seven African countries included
FDC-ALU that ranged from one to 58 months past expiry
date, with a mode and median age of two months at ini-
tial testing in July 2008 and nine months at retesting in
February 2009.
Of the two Lumartem samples tested in July 2008, both
passed TLC, disintegration and Raman spectrometry test-
ing. Of the 68 Coartem/Riamet samples tested in July
2008, all passed thin-layer chromatography (TLC) testing,
and nearly all passed disintegration and Raman spectrom-
etry testing, with the following exceptions: both replicates
of a Coartem/Riamet sample at 14 months past expiry
date failed Raman spectrometry testing, and one replicate
of a Coartem/Riamet sample 58 months past expiry date
failed the disintegration test (see Table 1). The blister
packages of the failing medicines showed visible signs of
minor damage, which may have been sufficient to spoil
the chemical and physical integrity of those tablets.
Notwithstanding equivalent active ingredients, there were
discernable differences between Coartem/Riamet and
Lumartem samples in Raman spectrometry owing to dif-
ferences in excipients. Samples of one manufacturer's
medicine run against the other manufacturer's standard
consistently failed the test (p < 0.05), both indicating that
p-values for the two medicines are not comparable, and
validating the Raman method as possessing sufficient sen-
sitivity to "fail" a medicine for differences apart from the
presence of active pharmaceutical ingredients. Within the
Coartem/Riamet sample pool, Raman spectrometry dem-
onstrated quality variations that were undetected by TLC.
Figure 1 demonstrates example spectra for Coartem/
Riamet samples that failed (p = 0.004) and passed (p =
0.388). For passing samples of Coartem/Riamet on initial
testing, there appears to be a weak inverse relationship
between sample p-value and the natural log transformed
age of the product past date (Figure 2; R2 = 0.33 by linear
regression). This is consistent with the expected behavior
of cumulative chemical degradation in samples over time,
where the sample population reflects storage under heter-
ogeneous field conditions and therefore varying rates of
degradation.
Table 1: Testing results for Coartem/Riamet by expiry date for Raman spectrometry, TLC and disintegration
July 2008 Test Resultsa February 2009 Test Resultsa
Expiry Date Number of Samples Number of Months 
Past Expiry Date
TLC Disintegration Raman Number of Months 
Past Expiry Date
Raman
June 2008 7 1 7/7 7/7 7/7 8 7/7
May 2008 39 2 39/39 39/39 39/39 9 39/39
February 2008 4 5 4/4 4/4 4/4 12 4/4
August 2007 7 11 7/7 7/7 7/7 18 7/7
May 2007 2 14 2/2 2/2 1/2 21 1/2
November 2006 3 20 3/3 3/3 3/3 27 3/3
October 2005 5 33 5/5 5/5 5/5 40 5/5
September 2003 1 58 1/1 0/1 1/1 65 0/1
Total 68/68 67/68 67/68 66/68
a. Results are total number of samples that passed testing/total samples tested.Malaria Journal 2009, 8:33 http://www.malariajournal.com/content/8/1/33
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Of the 68 Coartem/Riamet samples retested in February
2009 using Raman spectrometry, the results were consist-
ent with those from July 2008 (see Table 1) with the fol-
lowing exception: one replicate of the Coartem/Riamet
sample that had passed at 58 months past expiry date in
July 2008, failed at 65 months past expiry date and was
therefore recorded as a borderline fail. Overall, 66 of 68
(97%) samples passed Raman spectrometry retesting.
There were not sufficient tablets from every sample to
retest TLC and disintegration. Over the seven month
period from July 2008 to February 2009, the samples
remained relatively stable despite a decline in the mean
sample p-value from 0.39 to 0.28 respectively. This reduc-
tion in p-value is expected given the chemical degradation
in samples over time. Figure 3 is a scatter plot of the sam-
ple p-values from initial testing and retesting.
Further, in a fortuitous observation, the authors found
evidence that health ministry supply chains in some Afri-
can countries are corrupted. In the course of matching
batch numbers to verify the authenticity of the test sam-
ples, it was accidentally discovered that a batch of Coar-
tem sold to the Nigerian Government strictly for public
sector use, at concessional pricing had been illicitly
diverted, and was on sale in a private pharmacy in Kenya.
In another instance, two batches of Coartem sold to eight
different African governments were found on sale in a pri-
vate pharmacy in Rwanda.
Discussion and conclusion
These results provide a strong indication FDC-ALU is a far
more robust medicine in uncontrolled African conditions
(i.e. tropical conditions) than is currently credited. Of 70
samples, the authors found that all of them contained an
Raman spectrum of passed and failed Coartem/Riamet and reference Figure 1
Raman spectrum of passed and failed Coartem/Riamet and reference. Plot of passed (p-value 0.388) and failed (p-
value 0.004) Coartem/Riamet sample spectrum and reference spectrum, illustrated as counts (absolute measure of Raman 
intensity) versus Raman shift. The steep slope of the failed Coartem/Riamet sample is due to increased fluorescence of degra-
dation products.Malaria Journal 2009, 8:33 http://www.malariajournal.com/content/8/1/33
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acceptable amount of active ingredients by the TLC
method. Only one sample failed by the more exacting
method of Raman spectrometry on initial testing, and
another one sample failed disintegration testing. Overall
on initial testing, 68/70 (97%) samples passed, including
samples that were up to 33 months past their expiry date.
A limitation of this study is that its findings are generally
only valid for Coartem/Riamet. The limitation is as
expected: Coartem/Riamet was the first FDC-ALU to have
entered the marketplace, and owing to a not-for-profit dis-
tribution agreement between Novartis AG and the WHO,
it remains dominant. Few generic manufacturers, such as
GVS Labs, Ajanta Pharma Ltd. and Jiangsu Yixing Forward
Pharmaceutical Factory were manufacturing large quanti-
ties of FDC-ALU prior to 2006, and as such, their products
are less available in the marketplace, and when they are
encountered, are usually too recent to have passed their
expiry date. The authors located two expired samples of
Lumartem, manufactured by Cipla Ltd, which passed the
battery of initial tests.
These data are useful, but not sufficient for a shelf-life
extension. A more complete protocol would entail high
performance liquid chromatography (HPLC) and/or tan-
dem mass spectrometry analysis of degradation products;
testing of package stability; testing for biological contam-
ination; and possibly other tests as would be mandated by
a drug regulator. However, while these studies are often
done on medicines that have aged in controlled labora-
tory conditions, the advantage of this study is that it exam-
ines medicines kept in uncontrolled real-world
conditions in tropical Africa. Since these conditions can-
not always be accurately emulated in the laboratory – for
example, a test designed to mimic stability of a product in
a pharmacy's enclosed shelf may not approximate an
open-air market pharmacy's presentation in full sunlight
– these data should be viewed as complementary to the
future laboratory studies previously recommended.
An advantage of this study is that it demonstrates reliable
drug quality testing can be done without advanced analyt-
ical laboratories. The TLC and Raman techniques utilized
in this study are not a substitute for the laboratory-based
"gold standard" of HPLC or mass spectrometry, but are
validated as "silver standard", which is easily field-deploy-
able and which reliably detects deviations from a known
reference medicine – and unlike an HPLC laboratory, the
Degradation of Coartem/Riamet over time Figure 2
Degradation of Coartem/Riamet over time. Scatter plot of TruScan calculated p-values for all passing Coartem/Riamet 
samples versus natural log of months past expiry date.
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TruScan used in this study runs on battery power and fits
in a person's hands. Drug quality surveillance from man-
ufacturer to point-of-use likely requires both the gold and
silver standard; it is not one or the other.
Until now, it has been assumed that supply-and-demand
management for ACT could be simplified by stock-piling
artemisinin or its derivatives, rather than finished prod-
ucts, as these tend to be over 99% stable when stored at 25
degrees Centigrade and 60% relative humidity [5]. While
that is an attractive option, it also may not be necessary, as
the stability of FDC-ALU is reasonably stable for about
this same duration. The authors encountered apparently
stable samples of 57 months in age on initial testing (= 24
months shelf-life + 33 months post-expiry).
A problem that all manufacturers of FDC-ALU have is that
a 24-month shelf-life requires extraordinarily tight and
difficult control over production schedules and supply
chains. At the front end, the lead time is 14 months to cul-
tivate and extract Artemesia annua and to carry out the
manufacturing process; and at the back end, purchasers'
demand 18 or more months of remaining product life
upon receipt of product [10]. The former fact means that
unless the manufacturer holds some product in inventory,
then a purchaser who experiences a sudden rise in
demand (as during an epidemic or complex emergency)
cannot have that need met. The latter fact means that if the
manufacturer actually holds product in inventory, it runs
a serious financial risk because at only six months of age
the product becomes unsalable. This is an invidious situ-
ation for manufacturers of FDC-ALU, who must choose
between erring on the side of over-production and possi-
ble financial loss, or under-production and possible
health crises. Such a tight market is also prone to price
excursions, as have occurred for artemisinin before [5].
The unexpected observation of product diversion suggests
that there is also scope to improve public sector medicine
logistics in Africa. Such instances of diversion, besides
being illegal, suggest that the public sector controls over
FDC-ALU stocks are inaccurate. Inaccurate controls in this
instance meant theft, but are also likely to be associated
with mismanagement of medicines with a short shelf-life,
leading to wastage.
The authors' findings argue for a reevaluation of the shelf-
life of FDC-ALU, if confirmed by future studies using
more advanced analytical techniques, which for the policy
reasons already described would be very desirable.
Improving access to medicines will require many different
interventions that will vary from country to country. How-
Comparison of initial and retest Coartem/Riamet p-values Figure 3
Comparison of initial and retest Coartem/Riamet p-values. Scatter plot of Coartem/Riamet initial and retest TruScan 
calculated p-values versus natural log of months past expiry date.
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ever, extending the shelf-life of ACTs would be of benefit
in every country, which is why it should be a high priority,
with hopefully many more lives saved as a result.
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